Iceland· IS-EU/1/25/1924/001

Imreplys

A sargramostim product containing sargramostim, registered in Iceland by Partner Therapeutics Limited. The same ATC class is registered in 11 of our 19 countries.

ATC L03AA09

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedImreplysATCL03AA09REGISTER NO.IS-EU/1/25/1924/001PACKS LISTED0CHECKEDSeptember 29, 2026

Where it is registered

Sargramostim is registered in 11 of 19 countries.

Countries holding a registration under ATC L03AA09 (sargramostim), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 7 of them publish a price we can compare per daily dose

Sargramostim · ATC L03AA09

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Sargramostim
Manufacturer
Partner Therapeutics Limited
Country
Iceland (IS)
ATC code
L03AA09
ATC class
Sargramostim
Defined daily dose
0.45 mg, P
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

191 interactions on record for sargramostim.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Sargramostim · interactions on record

191 records

  • 2 severe
  • 189 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • CyclophosphamideL01AA01moderate
  • ChlorambucilL01AA02moderate
  • MelphalanL01AA03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f842bb13-d7c4-49bb-9eb6-d8bb114ba58a
GET /v1/drugs/f842bb13-d7c4-49bb-9eb6-d8bb114ba58a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Stungulyfsstofn, lausn",
  "source": "lyfjastofnun",
  "atc_raw": "L03AA09",
  "marketed": false,
  "strength": "250 míkróg",
  "ma_number": "EU/1/25/1924/001",
  "substance": "Sargramostim",
  "other_info": null,
  "legal_status": "(R) Lyfseðilsskylt",
  "ma_issued_serial": "45890"
}

See everything about sargramostim.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.